|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.75/-72.67
|
企业价值
35.14M
|
资产负债 |
每股账面净值
-0.59
|
现金流量 |
现金流量率
--
|
损益表 |
收益
12.00M
|
每股收益
0.53
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/30 18:34 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment. |